Zoetis Inc. $ZTS Shares Bought by Maryland State Retirement & Pension System

Maryland State Retirement & Pension System boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 2.6% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 21,690 shares of the company’s stock after purchasing an additional 542 shares during the period. Maryland State Retirement & Pension System’s holdings in Zoetis were worth $3,383,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Lindbrook Capital LLC increased its position in shares of Zoetis by 1.8% during the 1st quarter. Lindbrook Capital LLC now owns 3,715 shares of the company’s stock worth $612,000 after purchasing an additional 65 shares in the last quarter. Scott & Selber Inc. increased its position in Zoetis by 0.6% in the 2nd quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock valued at $1,817,000 after acquiring an additional 67 shares in the last quarter. Secure Asset Management LLC increased its position in Zoetis by 2.9% in the 2nd quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock valued at $382,000 after acquiring an additional 68 shares in the last quarter. Quotient Wealth Partners LLC increased its position in Zoetis by 2.3% in the 1st quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company’s stock valued at $521,000 after acquiring an additional 72 shares in the last quarter. Finally, Menard Financial Group LLC increased its position in Zoetis by 3.8% in the 1st quarter. Menard Financial Group LLC now owns 2,032 shares of the company’s stock valued at $305,000 after acquiring an additional 75 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Stifel Nicolaus cut shares of Zoetis from a “buy” rating to a “hold” rating and lowered their price objective for the company from $165.00 to $160.00 in a research report on Wednesday, June 18th. Argus restated a “buy” rating and issued a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday. Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Leerink Partnrs cut shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Five investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $200.88.

Zoetis Stock Down 0.1%

Zoetis stock opened at $143.32 on Friday. The company’s 50 day simple moving average is $149.36 and its 200 day simple moving average is $154.60. Zoetis Inc. has a fifty-two week low of $139.34 and a fifty-two week high of $196.55. The firm has a market capitalization of $63.52 billion, a price-to-earnings ratio of 24.67, a PEG ratio of 2.30 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The business had revenue of $2.46 billion for the quarter, compared to analyst estimates of $2.41 billion. During the same quarter last year, the firm earned $1.56 EPS. Zoetis’s quarterly revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.